The Phase 1 study with Kevetrin, CTIX-0000, is in progress at DanaFarber/Harvard
Cancer Center in subjects with various solid carcinomas;
the majority of which are gynecological cancers.
10 cohorts of subjects have been completed; the 11
th cohort is ongoing.
Only 1 DLT has been observed to date, but the MTD has not yet been
reached. The current dose is 750 mg/m2
, 75-fold greater than the starting
Kevetrin was shown to activate wild type p53 and degrade mutant p53.
Since Kevetrin activates both transcriptional-dependent and
transcriptional-independent pathways to promote apoptosis through wild
type p53 activation and degrades oncogenic mutant p53, Kevetrin can
function as a major inducer of apoptosis in many types of tumors
independent of p53 mutation status.
In this Phase 1 study, the biomarker, p21 expression levels in peripheral
blood, were increased in 68% of subjects and 48% had an increase in p21
expression at a level of ≥10%. These results suggest that Kevetrin activates
p53 by inducing p21 gene expression.
It use to be creating an environment for growth where business is inclined to invest here so people can have opportunity.
I guess that' why 90+% of the Government run economies are doing so well by making the standard of living going down, down, down with all their anti-business, high taxes, massive regulations...etc. I looked into starting several businesses over the past 6 years, I just can't take the risk given all the mandates, reg's, and the taxes make the ROI not worth the headache.
They can't release K data until ASCO. Part of the agreement to presenting at the conference. I would be loading up more, but maxed out.
add another $100 to my $250 PT.
Why, I am planning to buy more on these dips. I remember Durata all too well. This is at minimum a $100 stock, so think long term. I remember posts like this on the DRTX message board. Folks go out then bam, bought out for $23 + $5 in CVRs.
No data leak. They are actually doing quite a bit, they don't blast press releases. They could do a better job of keeping investors updated.
Nothing different. What do you folks want. They are giving an update next week, and one at ASCO. They are moving in the right direction on all fronts. Quit expecting more than has been communicated.
Most don't put news wires out until the conference and the significance is explained. There is massive accumulation, so my view is those in the know are buying all they can. I've bought all I can, broke all my diversification weighting rules. No firm is coming out with a high PT when they are accumulating. $50 is a joke IMHO.